nodes	percent_of_prediction	percent_of_DWPC	metapath
Leflunomide—CYP2C9—cardial valve—dilated cardiomyopathy	0.0823	0.383	CbGeAlD
Leflunomide—Vasculitis necrotising—Furosemide—dilated cardiomyopathy	0.0278	0.0437	CcSEcCtD
Leflunomide—DHODH—heart—dilated cardiomyopathy	0.0247	0.115	CbGeAlD
Leflunomide—DHODH—cardiac atrium—dilated cardiomyopathy	0.0211	0.0981	CbGeAlD
Leflunomide—AHR—cardiac ventricle—dilated cardiomyopathy	0.0196	0.091	CbGeAlD
Leflunomide—AHR—myocardium—dilated cardiomyopathy	0.0184	0.0856	CbGeAlD
Leflunomide—PTK2B—heart—dilated cardiomyopathy	0.0156	0.0726	CbGeAlD
Leflunomide—AHR—heart—dilated cardiomyopathy	0.0128	0.0597	CbGeAlD
Leflunomide—Ulcer—Spironolactone—dilated cardiomyopathy	0.0113	0.0178	CcSEcCtD
Leflunomide—AHR—cardiac atrium—dilated cardiomyopathy	0.011	0.0511	CbGeAlD
Leflunomide—Vasculitis—Spironolactone—dilated cardiomyopathy	0.011	0.0172	CcSEcCtD
Leflunomide—Cramps of lower extremities—Spironolactone—dilated cardiomyopathy	0.00983	0.0154	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00932	0.0625	CbGpPWpGaD
Leflunomide—Bursitis—Lisinopril—dilated cardiomyopathy	0.00903	0.0142	CcSEcCtD
Leflunomide—Appetite absent—Lisinopril—dilated cardiomyopathy	0.00878	0.0138	CcSEcCtD
Leflunomide—Cholestasis—Furosemide—dilated cardiomyopathy	0.00766	0.012	CcSEcCtD
Leflunomide—Pelvic pain—Lisinopril—dilated cardiomyopathy	0.00718	0.0113	CcSEcCtD
Leflunomide—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00699	0.011	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00699	0.011	CcSEcCtD
Leflunomide—Psoriasis—Lisinopril—dilated cardiomyopathy	0.00695	0.0109	CcSEcCtD
Leflunomide—Gastritis—Spironolactone—dilated cardiomyopathy	0.00687	0.0108	CcSEcCtD
Leflunomide—Eosinophilia—Spironolactone—dilated cardiomyopathy	0.00664	0.0104	CcSEcCtD
Leflunomide—PTK2B—FGF signaling pathway—PSEN1—dilated cardiomyopathy	0.00608	0.0408	CbGpPWpGaD
Leflunomide—Throat sore—Lisinopril—dilated cardiomyopathy	0.00606	0.00952	CcSEcCtD
Leflunomide—Hyperlipidaemia—Lisinopril—dilated cardiomyopathy	0.00606	0.00952	CcSEcCtD
Leflunomide—Oropharyngeal discomfort—Lisinopril—dilated cardiomyopathy	0.006	0.00944	CcSEcCtD
Leflunomide—Vasculitis—Furosemide—dilated cardiomyopathy	0.00596	0.00937	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.00593	0.00933	CcSEcCtD
Leflunomide—Renal failure—Spironolactone—dilated cardiomyopathy	0.00588	0.00925	CcSEcCtD
Leflunomide—Herpes zoster—Lisinopril—dilated cardiomyopathy	0.0058	0.00912	CcSEcCtD
Leflunomide—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00558	0.00878	CcSEcCtD
Leflunomide—DHODH—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00549	0.0368	CbGpPWpGaD
Leflunomide—Cramps of lower extremities—Furosemide—dilated cardiomyopathy	0.00535	0.00841	CcSEcCtD
Leflunomide—Endocrine disorder—Lisinopril—dilated cardiomyopathy	0.00527	0.00828	CcSEcCtD
Leflunomide—Bladder pain—Furosemide—dilated cardiomyopathy	0.00526	0.00827	CcSEcCtD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.00517	0.0347	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—VCL—dilated cardiomyopathy	0.00515	0.0346	CbGpPWpGaD
Leflunomide—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00508	0.00799	CcSEcCtD
Leflunomide—ABCG2—heart—dilated cardiomyopathy	0.00498	0.0232	CbGeAlD
Leflunomide—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.00486	0.00764	CcSEcCtD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—VCL—dilated cardiomyopathy	0.00485	0.0325	CbGpPWpGaD
Leflunomide—Oropharyngeal pain—Lisinopril—dilated cardiomyopathy	0.0048	0.00755	CcSEcCtD
Leflunomide—Arthropathy—Lisinopril—dilated cardiomyopathy	0.0048	0.00755	CcSEcCtD
Leflunomide—Cough increased—Lisinopril—dilated cardiomyopathy	0.00477	0.0075	CcSEcCtD
Leflunomide—Alopecia—Spironolactone—dilated cardiomyopathy	0.00475	0.00746	CcSEcCtD
Leflunomide—CYP2C9—heart—dilated cardiomyopathy	0.00455	0.0212	CbGeAlD
Leflunomide—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.0045	0.00707	CcSEcCtD
Leflunomide—Vasculitis—Lisinopril—dilated cardiomyopathy	0.00447	0.00703	CcSEcCtD
Leflunomide—Neck pain—Lisinopril—dilated cardiomyopathy	0.00442	0.00695	CcSEcCtD
Leflunomide—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00436	0.00686	CcSEcCtD
Leflunomide—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00434	0.00682	CcSEcCtD
Leflunomide—PTK2B—Alpha4 beta1 integrin signaling events—ITGB1—dilated cardiomyopathy	0.00434	0.0291	CbGpPWpGaD
Leflunomide—Cystitis noninfective—Lisinopril—dilated cardiomyopathy	0.00426	0.00671	CcSEcCtD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—ITGB1—dilated cardiomyopathy	0.00424	0.0284	CbGpPWpGaD
Leflunomide—Malaise—Spironolactone—dilated cardiomyopathy	0.00422	0.00663	CcSEcCtD
Leflunomide—Cystitis—Lisinopril—dilated cardiomyopathy	0.00422	0.00663	CcSEcCtD
Leflunomide—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00419	0.00658	CcSEcCtD
Leflunomide—Bladder pain—Lisinopril—dilated cardiomyopathy	0.00395	0.00621	CcSEcCtD
Leflunomide—Discomfort—Spironolactone—dilated cardiomyopathy	0.00393	0.00618	CcSEcCtD
Leflunomide—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00384	0.00604	CcSEcCtD
Leflunomide—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00382	0.006	CcSEcCtD
Leflunomide—Cramp muscle—Furosemide—dilated cardiomyopathy	0.0038	0.00598	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.0038	0.00598	CcSEcCtD
Leflunomide—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00374	0.00587	CcSEcCtD
Leflunomide—AHR—Adipogenesis—LMNA—dilated cardiomyopathy	0.0037	0.0249	CbGpPWpGaD
Leflunomide—PTK2B—Osteopontin-mediated events—RAC1—dilated cardiomyopathy	0.00367	0.0246	CbGpPWpGaD
Leflunomide—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.00366	0.00576	CcSEcCtD
Leflunomide—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00364	0.00573	CcSEcCtD
Leflunomide—Eosinophilia—Furosemide—dilated cardiomyopathy	0.00361	0.00568	CcSEcCtD
Leflunomide—Pancreatitis—Furosemide—dilated cardiomyopathy	0.00358	0.00563	CcSEcCtD
Leflunomide—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.00358	0.00562	CcSEcCtD
Leflunomide—Eczema—Lisinopril—dilated cardiomyopathy	0.00353	0.00555	CcSEcCtD
Leflunomide—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00353	0.00555	CcSEcCtD
Leflunomide—PTK2B—Alpha4 beta1 integrin signaling events—RAC1—dilated cardiomyopathy	0.00349	0.0234	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—ACTN2—dilated cardiomyopathy	0.00339	0.0228	CbGpPWpGaD
Leflunomide—Pollakiuria—Furosemide—dilated cardiomyopathy	0.00337	0.0053	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00329	0.00518	CcSEcCtD
Leflunomide—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00329	0.00518	CcSEcCtD
Leflunomide—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00327	0.00515	CcSEcCtD
Leflunomide—Arthritis—Lisinopril—dilated cardiomyopathy	0.00326	0.00513	CcSEcCtD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.00323	0.0217	CbGpPWpGaD
Leflunomide—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00323	0.00507	CcSEcCtD
Leflunomide—Renal failure—Furosemide—dilated cardiomyopathy	0.0032	0.00503	CcSEcCtD
Leflunomide—PTK2B—IL-2 Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00318	0.0214	CbGpPWpGaD
Leflunomide—Osteoarthritis—Lisinopril—dilated cardiomyopathy	0.00317	0.00498	CcSEcCtD
Leflunomide—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00314	0.00494	CcSEcCtD
Leflunomide—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.00308	0.00484	CcSEcCtD
Leflunomide—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00304	0.00478	CcSEcCtD
Leflunomide—Urticaria—Spironolactone—dilated cardiomyopathy	0.00303	0.00477	CcSEcCtD
Leflunomide—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00302	0.00474	CcSEcCtD
Leflunomide—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00289	0.00454	CcSEcCtD
Leflunomide—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00286	0.0045	CcSEcCtD
Leflunomide—Breast disorder—Lisinopril—dilated cardiomyopathy	0.00286	0.0045	CcSEcCtD
Leflunomide—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00285	0.00449	CcSEcCtD
Leflunomide—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.00285	0.00449	CcSEcCtD
Leflunomide—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.00281	0.00442	CcSEcCtD
Leflunomide—Gastritis—Lisinopril—dilated cardiomyopathy	0.0028	0.00441	CcSEcCtD
Leflunomide—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00276	0.00434	CcSEcCtD
Leflunomide—Influenza—Lisinopril—dilated cardiomyopathy	0.00274	0.00431	CcSEcCtD
Leflunomide—Asthma—Lisinopril—dilated cardiomyopathy	0.00274	0.00431	CcSEcCtD
Leflunomide—Eye disorder—Furosemide—dilated cardiomyopathy	0.00273	0.00429	CcSEcCtD
Leflunomide—Eosinophilia—Lisinopril—dilated cardiomyopathy	0.00271	0.00426	CcSEcCtD
Leflunomide—Pruritus—Spironolactone—dilated cardiomyopathy	0.0027	0.00425	CcSEcCtD
Leflunomide—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.00269	0.00422	CcSEcCtD
Leflunomide—Sweating increased—Lisinopril—dilated cardiomyopathy	0.00267	0.0042	CcSEcCtD
Leflunomide—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.00267	0.0042	CcSEcCtD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—RPS6KB1—dilated cardiomyopathy	0.00264	0.0177	CbGpPWpGaD
Leflunomide—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00264	0.00415	CcSEcCtD
Leflunomide—Bronchitis—Lisinopril—dilated cardiomyopathy	0.00263	0.00414	CcSEcCtD
Leflunomide—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.00261	0.00411	CcSEcCtD
Leflunomide—Arrhythmia—Furosemide—dilated cardiomyopathy	0.00261	0.0041	CcSEcCtD
Leflunomide—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.0026	0.00409	CcSEcCtD
Leflunomide—Dysuria—Lisinopril—dilated cardiomyopathy	0.00256	0.00403	CcSEcCtD
Leflunomide—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00256	0.00403	CcSEcCtD
Leflunomide—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00255	0.004	CcSEcCtD
Leflunomide—Malnutrition—Furosemide—dilated cardiomyopathy	0.00254	0.004	CcSEcCtD
Leflunomide—Dizziness—Spironolactone—dilated cardiomyopathy	0.00252	0.00397	CcSEcCtD
Leflunomide—Flatulence—Furosemide—dilated cardiomyopathy	0.00251	0.00394	CcSEcCtD
Leflunomide—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00249	0.00392	CcSEcCtD
Leflunomide—Weight decreased—Lisinopril—dilated cardiomyopathy	0.00248	0.0039	CcSEcCtD
Leflunomide—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00247	0.00389	CcSEcCtD
Leflunomide—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00246	0.00386	CcSEcCtD
Leflunomide—Muscle spasms—Furosemide—dilated cardiomyopathy	0.00245	0.00385	CcSEcCtD
Leflunomide—Vomiting—Spironolactone—dilated cardiomyopathy	0.00243	0.00381	CcSEcCtD
Leflunomide—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00242	0.00381	CcSEcCtD
Leflunomide—Rash—Spironolactone—dilated cardiomyopathy	0.00241	0.00378	CcSEcCtD
Leflunomide—Dermatitis—Spironolactone—dilated cardiomyopathy	0.0024	0.00378	CcSEcCtD
Leflunomide—Renal failure—Lisinopril—dilated cardiomyopathy	0.0024	0.00377	CcSEcCtD
Leflunomide—Vision blurred—Furosemide—dilated cardiomyopathy	0.0024	0.00377	CcSEcCtD
Leflunomide—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00239	0.00376	CcSEcCtD
Leflunomide—Headache—Spironolactone—dilated cardiomyopathy	0.00239	0.00376	CcSEcCtD
Leflunomide—Jaundice—Lisinopril—dilated cardiomyopathy	0.00238	0.00374	CcSEcCtD
Leflunomide—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00237	0.00373	CcSEcCtD
Leflunomide—Anaemia—Furosemide—dilated cardiomyopathy	0.00235	0.0037	CcSEcCtD
Leflunomide—Haematuria—Lisinopril—dilated cardiomyopathy	0.00233	0.00366	CcSEcCtD
Leflunomide—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00231	0.00363	CcSEcCtD
Leflunomide—Epistaxis—Lisinopril—dilated cardiomyopathy	0.0023	0.00362	CcSEcCtD
Leflunomide—PTK2B—Integrins in angiogenesis—RPS6KB1—dilated cardiomyopathy	0.0023	0.0154	CbGpPWpGaD
Leflunomide—Sinusitis—Lisinopril—dilated cardiomyopathy	0.00229	0.0036	CcSEcCtD
Leflunomide—Vertigo—Furosemide—dilated cardiomyopathy	0.00229	0.00359	CcSEcCtD
Leflunomide—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00228	0.00358	CcSEcCtD
Leflunomide—Leukopenia—Furosemide—dilated cardiomyopathy	0.00228	0.00358	CcSEcCtD
Leflunomide—Nausea—Spironolactone—dilated cardiomyopathy	0.00227	0.00356	CcSEcCtD
Leflunomide—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—RAF1—dilated cardiomyopathy	0.00226	0.0151	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.00221	0.0149	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.00221	0.0149	CbGpPWpGaD
Leflunomide—Rhinitis—Lisinopril—dilated cardiomyopathy	0.0022	0.00346	CcSEcCtD
Leflunomide—Hepatitis—Lisinopril—dilated cardiomyopathy	0.00219	0.00345	CcSEcCtD
Leflunomide—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00218	0.00342	CcSEcCtD
Leflunomide—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00217	0.0034	CcSEcCtD
Leflunomide—AHR—Adipogenesis—FAS—dilated cardiomyopathy	0.00216	0.0145	CbGpPWpGaD
Leflunomide—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00216	0.0034	CcSEcCtD
Leflunomide—DHODH—Metabolism—ANKRD1—dilated cardiomyopathy	0.00216	0.0145	CbGpPWpGaD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00215	0.00338	CcSEcCtD
Leflunomide—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00215	0.00338	CcSEcCtD
Leflunomide—Dry mouth—Furosemide—dilated cardiomyopathy	0.00212	0.00333	CcSEcCtD
Leflunomide—AHR—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.00211	0.0142	CbGpPWpGaD
Leflunomide—AHR—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.00211	0.0142	CbGpPWpGaD
Leflunomide—PTK2B—Integrins in angiogenesis—RAC1—dilated cardiomyopathy	0.00208	0.0139	CbGpPWpGaD
Leflunomide—PTK2B—Endothelins—RAC1—dilated cardiomyopathy	0.00208	0.0139	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00208	0.00326	CcSEcCtD
Leflunomide—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00207	0.00326	CcSEcCtD
Leflunomide—PTK2B—LPA receptor mediated events—RAC1—dilated cardiomyopathy	0.00205	0.0138	CbGpPWpGaD
Leflunomide—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00204	0.0032	CcSEcCtD
Leflunomide—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00203	0.0032	CcSEcCtD
Leflunomide—DHODH—Metabolism—TAZ—dilated cardiomyopathy	0.00203	0.0136	CbGpPWpGaD
Leflunomide—AHR—Adipogenesis—AGT—dilated cardiomyopathy	0.00203	0.0136	CbGpPWpGaD
Leflunomide—Skin disorder—Furosemide—dilated cardiomyopathy	0.00202	0.00317	CcSEcCtD
Leflunomide—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00201	0.00316	CcSEcCtD
Leflunomide—Anorexia—Furosemide—dilated cardiomyopathy	0.00198	0.00311	CcSEcCtD
Leflunomide—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00198	0.00311	CcSEcCtD
Leflunomide—Chills—Lisinopril—dilated cardiomyopathy	0.00197	0.00309	CcSEcCtD
Leflunomide—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00196	0.00308	CcSEcCtD
Leflunomide—Hypotension—Furosemide—dilated cardiomyopathy	0.00194	0.00305	CcSEcCtD
Leflunomide—Alopecia—Lisinopril—dilated cardiomyopathy	0.00194	0.00305	CcSEcCtD
Leflunomide—Mental disorder—Lisinopril—dilated cardiomyopathy	0.00192	0.00302	CcSEcCtD
Leflunomide—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00191	0.003	CcSEcCtD
Leflunomide—PTK2B—IL-2 Signaling Pathway—RAF1—dilated cardiomyopathy	0.00191	0.0128	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.00188	0.0126	CbGpPWpGaD
Leflunomide—Flatulence—Lisinopril—dilated cardiomyopathy	0.00188	0.00296	CcSEcCtD
Leflunomide—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.00187	0.00294	CcSEcCtD
Leflunomide—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00186	0.00293	CcSEcCtD
Leflunomide—Back pain—Lisinopril—dilated cardiomyopathy	0.00185	0.0029	CcSEcCtD
Leflunomide—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.00184	0.00289	CcSEcCtD
Leflunomide—DHODH—Metabolism—SDHA—dilated cardiomyopathy	0.00183	0.0123	CbGpPWpGaD
Leflunomide—Decreased appetite—Furosemide—dilated cardiomyopathy	0.0018	0.00284	CcSEcCtD
Leflunomide—Vision blurred—Lisinopril—dilated cardiomyopathy	0.0018	0.00283	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00179	0.00282	CcSEcCtD
Leflunomide—Fatigue—Furosemide—dilated cardiomyopathy	0.00179	0.00281	CcSEcCtD
Leflunomide—Pain—Furosemide—dilated cardiomyopathy	0.00178	0.00279	CcSEcCtD
Leflunomide—Constipation—Furosemide—dilated cardiomyopathy	0.00178	0.00279	CcSEcCtD
Leflunomide—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00177	0.00278	CcSEcCtD
Leflunomide—Anaemia—Lisinopril—dilated cardiomyopathy	0.00176	0.00277	CcSEcCtD
Leflunomide—Angioedema—Lisinopril—dilated cardiomyopathy	0.00174	0.00274	CcSEcCtD
Leflunomide—PTK2B—Interleukin-2 signaling—RAF1—dilated cardiomyopathy	0.00174	0.0117	CbGpPWpGaD
Leflunomide—Malaise—Lisinopril—dilated cardiomyopathy	0.00172	0.00271	CcSEcCtD
Leflunomide—Vertigo—Lisinopril—dilated cardiomyopathy	0.00171	0.0027	CcSEcCtD
Leflunomide—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00171	0.00269	CcSEcCtD
Leflunomide—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00171	0.00269	CcSEcCtD
Leflunomide—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.0017	0.00267	CcSEcCtD
Leflunomide—Palpitations—Lisinopril—dilated cardiomyopathy	0.00169	0.00265	CcSEcCtD
Leflunomide—Cough—Lisinopril—dilated cardiomyopathy	0.00167	0.00262	CcSEcCtD
Leflunomide—PTK2B—CXCR4-mediated signaling events—RAC1—dilated cardiomyopathy	0.00165	0.0111	CbGpPWpGaD
Leflunomide—Urticaria—Furosemide—dilated cardiomyopathy	0.00165	0.00259	CcSEcCtD
Leflunomide—Abdominal pain—Furosemide—dilated cardiomyopathy	0.00164	0.00258	CcSEcCtD
Leflunomide—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00164	0.00258	CcSEcCtD
Leflunomide—Chest pain—Lisinopril—dilated cardiomyopathy	0.00162	0.00255	CcSEcCtD
Leflunomide—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00162	0.00255	CcSEcCtD
Leflunomide—Myalgia—Lisinopril—dilated cardiomyopathy	0.00162	0.00255	CcSEcCtD
Leflunomide—Anxiety—Lisinopril—dilated cardiomyopathy	0.00162	0.00255	CcSEcCtD
Leflunomide—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00161	0.00254	CcSEcCtD
Leflunomide—Discomfort—Lisinopril—dilated cardiomyopathy	0.00161	0.00252	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—FAS—dilated cardiomyopathy	0.00159	0.0107	CbGpPWpGaD
Leflunomide—Dry mouth—Lisinopril—dilated cardiomyopathy	0.00159	0.0025	CcSEcCtD
Leflunomide—PTK2B—IL2-mediated signaling events—RAF1—dilated cardiomyopathy	0.00156	0.0105	CbGpPWpGaD
Leflunomide—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00156	0.00245	CcSEcCtD
Leflunomide—Infection—Lisinopril—dilated cardiomyopathy	0.00155	0.00243	CcSEcCtD
Leflunomide—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.00153	0.00241	CcSEcCtD
Leflunomide—AHR—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.00153	0.0102	CbGpPWpGaD
Leflunomide—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00153	0.0024	CcSEcCtD
Leflunomide—Tachycardia—Lisinopril—dilated cardiomyopathy	0.00152	0.00239	CcSEcCtD
Leflunomide—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00151	0.00238	CcSEcCtD
Leflunomide—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00151	0.00237	CcSEcCtD
Leflunomide—Asthenia—Furosemide—dilated cardiomyopathy	0.00149	0.00234	CcSEcCtD
Leflunomide—Anorexia—Lisinopril—dilated cardiomyopathy	0.00148	0.00233	CcSEcCtD
Leflunomide—Pruritus—Furosemide—dilated cardiomyopathy	0.00147	0.00231	CcSEcCtD
Leflunomide—Hypotension—Lisinopril—dilated cardiomyopathy	0.00146	0.00229	CcSEcCtD
Leflunomide—PTK2B—Cell-Cell communication—ITGB1—dilated cardiomyopathy	0.00145	0.00972	CbGpPWpGaD
Leflunomide—Diarrhoea—Furosemide—dilated cardiomyopathy	0.00142	0.00223	CcSEcCtD
Leflunomide—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.00142	0.00223	CcSEcCtD
Leflunomide—Insomnia—Lisinopril—dilated cardiomyopathy	0.00141	0.00222	CcSEcCtD
Leflunomide—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.0014	0.0022	CcSEcCtD
Leflunomide—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00139	0.00218	CcSEcCtD
Leflunomide—PTK2B—Endothelins—RAF1—dilated cardiomyopathy	0.00138	0.00925	CbGpPWpGaD
Leflunomide—Dizziness—Furosemide—dilated cardiomyopathy	0.00137	0.00216	CcSEcCtD
Leflunomide—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.00137	0.00216	CcSEcCtD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—RAC1—dilated cardiomyopathy	0.00136	0.00913	CbGpPWpGaD
Leflunomide—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00135	0.00213	CcSEcCtD
Leflunomide—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00134	0.00211	CcSEcCtD
Leflunomide—PTK2B—Oncostatin M Signaling Pathway—RAF1—dilated cardiomyopathy	0.00134	0.00902	CbGpPWpGaD
Leflunomide—Fatigue—Lisinopril—dilated cardiomyopathy	0.00134	0.00211	CcSEcCtD
Leflunomide—Pain—Lisinopril—dilated cardiomyopathy	0.00133	0.00209	CcSEcCtD
Leflunomide—Constipation—Lisinopril—dilated cardiomyopathy	0.00133	0.00209	CcSEcCtD
Leflunomide—Vomiting—Furosemide—dilated cardiomyopathy	0.00132	0.00208	CcSEcCtD
Leflunomide—Rash—Furosemide—dilated cardiomyopathy	0.00131	0.00206	CcSEcCtD
Leflunomide—Dermatitis—Furosemide—dilated cardiomyopathy	0.00131	0.00206	CcSEcCtD
Leflunomide—Headache—Furosemide—dilated cardiomyopathy	0.0013	0.00204	CcSEcCtD
Leflunomide—PTK2B—Signaling events mediated by VEGFR1 and VEGFR2—RAF1—dilated cardiomyopathy	0.0013	0.0087	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—RAC1—dilated cardiomyopathy	0.00128	0.00862	CbGpPWpGaD
Leflunomide—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00128	0.00202	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—GJA1—dilated cardiomyopathy	0.00128	0.0086	CbGpPWpGaD
Leflunomide—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00127	0.002	CcSEcCtD
Leflunomide—Urticaria—Lisinopril—dilated cardiomyopathy	0.00124	0.00195	CcSEcCtD
Leflunomide—CYP1A2—Melatonin metabolism and effects—ADRB1—dilated cardiomyopathy	0.00123	0.00828	CbGpPWpGaD
Leflunomide—Nausea—Furosemide—dilated cardiomyopathy	0.00123	0.00194	CcSEcCtD
Leflunomide—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.00123	0.00194	CcSEcCtD
Leflunomide—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00123	0.00194	CcSEcCtD
Leflunomide—PTK2B—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.00119	0.00797	CbGpPWpGaD
Leflunomide—PTK2B—Cell-Cell communication—RAC1—dilated cardiomyopathy	0.00116	0.00781	CbGpPWpGaD
Leflunomide—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.00115	0.0018	CcSEcCtD
Leflunomide—Asthenia—Lisinopril—dilated cardiomyopathy	0.00112	0.00176	CcSEcCtD
Leflunomide—Pruritus—Lisinopril—dilated cardiomyopathy	0.0011	0.00173	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.00108	0.00725	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.00107	0.0072	CbGpPWpGaD
Leflunomide—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.00107	0.00168	CcSEcCtD
Leflunomide—PTK2B—TCR Signaling Pathway—RAF1—dilated cardiomyopathy	0.00104	0.00695	CbGpPWpGaD
Leflunomide—PTK2B—Apoptosis-related network due to altered Notch3 in ovarian cancer—TNF—dilated cardiomyopathy	0.00103	0.00694	CbGpPWpGaD
Leflunomide—Dizziness—Lisinopril—dilated cardiomyopathy	0.00103	0.00162	CcSEcCtD
Leflunomide—Vomiting—Lisinopril—dilated cardiomyopathy	0.00099	0.00156	CcSEcCtD
Leflunomide—Rash—Lisinopril—dilated cardiomyopathy	0.000982	0.00154	CcSEcCtD
Leflunomide—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000981	0.00154	CcSEcCtD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	0.000976	0.00655	CbGpPWpGaD
Leflunomide—Headache—Lisinopril—dilated cardiomyopathy	0.000976	0.00153	CcSEcCtD
Leflunomide—PTK2B—LPA receptor mediated events—EGFR—dilated cardiomyopathy	0.000933	0.00626	CbGpPWpGaD
Leflunomide—Nausea—Lisinopril—dilated cardiomyopathy	0.000925	0.00145	CcSEcCtD
Leflunomide—AHR—Adipogenesis—TNF—dilated cardiomyopathy	0.000919	0.00616	CbGpPWpGaD
Leflunomide—PTK2B—VEGFA-VEGFR2 Pathway—RAF1—dilated cardiomyopathy	0.000902	0.00605	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by Interleukins—RAF1—dilated cardiomyopathy	0.000895	0.00601	CbGpPWpGaD
Leflunomide—AHR—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	0.000856	0.00574	CbGpPWpGaD
Leflunomide—PTK2B—Signaling by VEGF—RAF1—dilated cardiomyopathy	0.000852	0.00572	CbGpPWpGaD
Leflunomide—PTK2B—BDNF signaling pathway—RAF1—dilated cardiomyopathy	0.000711	0.00477	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000647	0.00434	CbGpPWpGaD
Leflunomide—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.00064	0.00429	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000569	0.00382	CbGpPWpGaD
Leflunomide—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000547	0.00367	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000531	0.00356	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000517	0.00347	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000517	0.00347	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—GPX1—dilated cardiomyopathy	0.000498	0.00334	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—CD36—dilated cardiomyopathy	0.000485	0.00326	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00048	0.00322	CbGpPWpGaD
Leflunomide—PTK2B—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	0.000444	0.00298	CbGpPWpGaD
Leflunomide—DHODH—Metabolism—AGT—dilated cardiomyopathy	0.000437	0.00293	CbGpPWpGaD
Leflunomide—PTK2B—Cytokine Signaling in Immune system—RAF1—dilated cardiomyopathy	0.000418	0.0028	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000396	0.00266	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000372	0.0025	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	0.000356	0.00239	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000349	0.00234	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000338	0.00227	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—TAZ—dilated cardiomyopathy	0.000328	0.0022	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000318	0.00213	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—SDHA—dilated cardiomyopathy	0.000297	0.00199	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—PSEN2—dilated cardiomyopathy	0.000265	0.00178	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—ITGB1—dilated cardiomyopathy	0.000256	0.00172	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000244	0.00164	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	0.000244	0.00164	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCL2—dilated cardiomyopathy	0.000235	0.00158	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AGTR2—dilated cardiomyopathy	0.000235	0.00158	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000232	0.00156	CbGpPWpGaD
Leflunomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	0.000232	0.00156	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—CXCR3—dilated cardiomyopathy	0.000218	0.00147	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—CD36—dilated cardiomyopathy	0.000218	0.00147	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ADRB1—dilated cardiomyopathy	0.000212	0.00142	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RAC1—dilated cardiomyopathy	0.000206	0.00138	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AGTR1—dilated cardiomyopathy	0.000181	0.00121	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	0.000176	0.00118	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—ADRB2—dilated cardiomyopathy	0.000171	0.00115	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	0.000166	0.00111	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000151	0.00101	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	0.00015	0.00101	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	0.000147	0.000989	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	0.000142	0.000951	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—RAF1—dilated cardiomyopathy	0.000136	0.000916	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RAC1—dilated cardiomyopathy	0.000133	0.000893	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	0.000128	0.00086	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—AGT—dilated cardiomyopathy	0.000127	0.000853	CbGpPWpGaD
Leflunomide—ABCG2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000105	0.000703	CbGpPWpGaD
Leflunomide—PTK2B—Immune System—EGFR—dilated cardiomyopathy	9.36e-05	0.000628	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	9.14e-05	0.000614	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	8.91e-05	0.000598	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—RAF1—dilated cardiomyopathy	8.82e-05	0.000592	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—GPX1—dilated cardiomyopathy	8.06e-05	0.000541	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	8.02e-05	0.000538	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—CD36—dilated cardiomyopathy	7.85e-05	0.000527	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	7.81e-05	0.000524	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	7.61e-05	0.000511	CbGpPWpGaD
Leflunomide—ABCG2—Metabolism—AGT—dilated cardiomyopathy	7.07e-05	0.000474	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	6.85e-05	0.00046	CbGpPWpGaD
Leflunomide—PTK2B—Signaling Pathways—EGFR—dilated cardiomyopathy	6.05e-05	0.000406	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	4.07e-05	0.000273	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	3.97e-05	0.000266	CbGpPWpGaD
Leflunomide—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	3.57e-05	0.00024	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	3.48e-05	0.000234	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	3.39e-05	0.000227	CbGpPWpGaD
Leflunomide—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	3.05e-05	0.000205	CbGpPWpGaD
